Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
SPECIAL ANNOUNCEMENT
2016 Photonics Buyers' Guide Clearance! – Use Coupon Code FC16 to save 60%!
share
Email Facebook Twitter Google+ LinkedIn Comments

Galileo Refocuses After Xerox Loss

Photonics Spectra
May 1997
Jennifer L. Morey

STURBRIDGE, Mass. -- Despite the loss of its biggest customer earlier this year and the resulting financial blow, Galileo Corp. officials are confident that the company will be able to get back on its feet by refocusing on its strategic objectives in the medical and telecommunications industries.
The day after Galileo announced that Xerox Corp. would no longer be purchasing its dicorotron assemblies, Galileo's stocks dropped nearly 12 points, from 185/8 on Feb. 12 to 67/8 on Feb. 13. Xerox's purchase of the photocopier components represented 48 percent, or $20.4 million, of Galileo's revenues for fiscal 1996.
Furthermore, Galileo reduced its work force by 16 percent, a total of 39 employees, and either postponed or eliminated a number of discretionary expenditures.
Galileo officials realize that the company will not immediately recover from the Xerox loss, but they are sticking to their original goals of developing growth-market products. President and CEO William Hanley thinks the company will reposition itself and regain profitability by the first quarter of 1998. "Our strategy of diversification into both medical and telecommunications products, as well as the continued health of our Scientific Detector Products Group, provides a strong foundation for future growth," he said.
Among the company's strategy areas is endoscopic imaging, according to Greg Riedel, the firm's chief financial officer. Consistent with this focus, Galileo's Medical Products Group recently received a multimillion-dollar order from Sofamor Danek for a single-use endoscope developed in a collaborative effort among the two companies. The device is for a minimally invasive spinal procedure that could eliminate the need for general anesthesia and reduce patients' hospital stays.
According to Riedel, dicorotron technology was "not a part of our growth strategy." And though Galileo is disappointed by the end of its relationship with Xerox, it can now concentrate on technologies for future markets.


Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x Subscribe to Photonics Spectra magazine - FREE!